halofuginone
Small moleculeexperimental
Halofuginone, sold under the brand name Halocur, is a coccidiostat used in veterinary medicine. It is a synthetic halogenated derivative of febrifugine, a natural quinazolinone alkaloid which can be found in the Chinese herb Dichroa febrifuga. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and it has received orphan drug designation from the U.S. Food and Drug Administration. — Wikipedia
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2001 (NCT00027677)
Timeline
Indications
Mechanism of action
- Growth/differentiation factor 8INHIBITOR
MSTN inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CC1NCCCC1O)Cn1cnc2cc(Br)c(Cl)cc2c1=O- Mol. weight
- 414.69 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1197091 ↗
- WikipediaHalofuginone ↗
- ChEMBLCHEMBL559362 ↗
Also known as
- 7-bromo-6-chloro- 3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)- quinazolinone
- 7-bromo-6-chlorofebrifugine
- halofuginone
- halofuginone
- halofuginone
- halofuginone
- halofuginone hydrobromide
- halofuginone hydrobromide
- halofuginone hydrobromide
- halofunginone
- ht-100
- ht-100
- ru-19110
- ru-19110
- stenorol
- stenorol
- stenorol
- (+/-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
- (+/-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02525302 | Phase 2 | May 1, 2015 | Akashi Therapeutics |
| NCT01978366 | Phase 2 | Oct 1, 2013 | Akashi Therapeutics |
| NCT01847573 | Phase 1/Phase 2 (Phase 2) | May 1, 2013 | Akashi Therapeutics |
| NCT00064142 | Phase 2 | May 1, 2003 | AIDS Malignancy Consortium, National Cancer Institute (NCI) |
| NCT00027677 | Phase 1 | Aug 1, 2001 | Erasmus University Rotterdam, European Organisation for Research and Treatment of Cancer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akashi Therapeutics | For profit | 3 | 3 | 1 | 2013 |
| AIDS Malignancy Consortium | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2001 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2001 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2003 |
5 organizations
Page 1 / 1